Anastrozole: mechanism of action
Anastrozole is a prescription medicine best known for its role in treating hormone-receptor-positive breast cancer in postmenopausal women. It belongs to a class called aromatase inhibitors, and it works by throttling the body's production of oestrogen. Because oestrogen also features in the side effects of anabolic steroid misuse, the drug has acquired an unofficial reputation outside medicine. The editorial team explains how anastrozole actually works, where it is genuinely useful, and why self-directed use is hazardous.
The enzyme at the centre: aromatase
To understand anastrozole you first have to understand aromatase, an enzyme that performs a single, pivotal conversion: it turns androgens such as testosterone and androstenedione into oestrogens, chiefly estradiol. This reaction is the main source of oestrogen in several tissues, including fat, muscle and, importantly, in the body after the ovaries stop producing oestrogen at menopause.
In premenopausal women the ovaries are the dominant oestrogen factory. After menopause, that source largely shuts down, and aromatase activity in peripheral tissues — fat in particular — becomes the main remaining supply. This shift is the key to why aromatase inhibitors are used specifically in postmenopausal women.
Oestrogen is not simply a female hormone to be eliminated. It is essential for bone density, cardiovascular health, cognition and more, in both sexes. Any drug that lowers it therefore has predictable consequences wherever oestrogen normally does useful work.
Anastrozole targets this enzyme directly. By doing so it reduces circulating oestrogen across the board, which is therapeutically valuable in cancers that are driven by oestrogen but costly in tissues that depend on it.
How anastrozole blocks oestrogen production
Anastrozole is a non-steroidal, reversible aromatase inhibitor. It binds to the aromatase enzyme and competes with the natural substrate, so that fewer androgen molecules are converted into oestrogen. Because the binding is reversible, the effect depends on the drug being present; it does not permanently destroy the enzyme the way some steroidal inhibitors do.
The result is a substantial fall in circulating estradiol. In the licensed setting — postmenopausal breast cancer — clinical studies have shown that standard dosing suppresses oestrogen levels markedly, which is precisely the intended effect when the tumour is oestrogen-driven.
It is worth distinguishing aromatase inhibitors from the other main class of anti-oestrogen therapy, the selective oestrogen receptor modulators such as tamoxifen. The difference is fundamental and is summarised below.
| Feature | Aromatase inhibitor (anastrozole) | SERM (tamoxifen) |
|---|---|---|
| Target | Aromatase enzyme | Oestrogen receptor |
| Effect on oestrogen level | Lowers production | Blocks/modulates receptor |
| Typical population | Postmenopausal | Pre- and postmenopausal |
| Bone effect | Tends to reduce density | Variable, can protect bone |
This mechanistic clarity matters: anastrozole lowers the supply of oestrogen, whereas a SERM changes how tissues respond to the oestrogen that is present. They are not interchangeable, and each has its own risk profile.
The licensed medical uses
Anastrozole's principal licensed use is the treatment of hormone-receptor-positive early and advanced breast cancer in postmenopausal women. Large randomised trials, notably the ATAC trial, established it as an effective option, with a different side-effect balance from tamoxifen. In suitable patients it reduces the risk of recurrence by depriving oestrogen-sensitive tumour cells of their stimulus.
It is prescribed and monitored by oncology specialists, who weigh its benefits against its effects on bone and other systems. The decision to use it, and for how long, rests on tumour characteristics, menopausal status and individual risk — not on a one-size-fits-all rule.
Beyond oncology, anastrozole is sometimes used under specialist endocrine supervision in selected conditions, such as certain cases investigated by endocrinologists. These are nuanced, individualised decisions made by clinicians with access to monitoring, and they are quite different from unsupervised use.
The common thread in every legitimate use is oversight: a diagnosis, a clear indication, dose decisions by a specialist, and regular monitoring of the consequences of lowering oestrogen. That framework is what makes the drug's powerful effect safe to deploy.
Why oestrogen suppression carries costs
Because oestrogen does important work throughout the body, driving its level down produces predictable side effects. The best-documented is on the skeleton: aromatase inhibitors accelerate bone loss and increase fracture risk, which is why patients on long-term therapy have their bone density monitored and may be offered protective treatment.
Other common effects reflect the same cause: joint aches and stiffness, hot flushes, fatigue, and changes in cholesterol. Mood changes and reduced libido can occur. In men, where oestrogen is derived largely from aromatisation of testosterone, suppressing it too far can harm bone, lipids, mood and sexual function.
This is the heart of the safety message. The side effects of anastrozole are not quirks; they are the logical result of removing a hormone the body relies on. The benefit in cancer therapy justifies that trade-off under supervision. Outside that context, the same effects become unmanaged harms.
The drug is also not something to combine casually with other agents. Its interactions and its impact on the hormonal axis require the kind of monitoring that only a clinical setting provides.
The danger of unsupervised use
Anastrozole has gained an underground reputation among some who misuse anabolic steroids, because high-dose steroids raise oestrogen through aromatisation and can cause effects such as breast tissue growth. Using a potent prescription aromatase inhibitor to counter this, without medical supervision, is hazardous and is not something this article will guide.
The reasons are straightforward. Oestrogen in men is essential, and crushing it carries real harms:
- Accelerated bone loss and higher fracture risk, even in young men.
- Worsened cholesterol profile and possible cardiovascular consequences.
- Loss of libido, erectile problems and low mood when oestrogen falls too far.
- Joint pain and fatigue that degrade the very training the user is pursuing.
Beyond the pharmacology, self-sourced products carry the usual risks of an unregulated market — wrong strength, wrong contents, no quality control. There is no safe way to self-titrate a drug whose effect you cannot measure without blood tests and clinical judgement.
The honest conclusion is that anastrozole is a valuable medicine in the right hands and a dangerous tool in the wrong ones. If oestrogen-related problems arise in any context, the answer is a doctor, not a prescription medicine bought without one.
Readers interested in this field may also wish to read our overviews of how oestrogen functions in men, of the SERM class such as tamoxifen, and of monitoring hormonal health, which provide useful background.
Conclusions of the editorial team
Anastrozole works by inhibiting aromatase, the enzyme that converts androgens into oestrogen, and thereby lowers oestrogen throughout the body. In postmenopausal breast cancer this mechanism is genuinely life-prolonging, which is why it is a cornerstone of hormone therapy.
But the same action that fights oestrogen-driven tumours also strips the body of a hormone it needs for bone, heart, brain and sexual health, producing predictable side effects that demand monitoring.
Used under specialist care it is a powerful, well-understood drug; used without supervision it is a liability. Anyone facing hormonal side effects, in any setting, should seek medical assessment rather than self-medicate.
References
- Howell A, Cuzick J, Baum M, et al. Results of the ATAC trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005;365(9453):60-62.
- Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability. Clin Cancer Res. 2001;7(9):2620-2635.
- Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med. 2003;348(24):2431-2442.
- Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the ATAC trial. J Clin Oncol. 2008;26(7):1051-1057.
- Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011-1022.
- Pope HG Jr, Wood RI, Rogol A, et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev. 2014;35(3):341-375.
